Health Care Professionals Partnering Careers Contact Us

Home > News & Media

Welcome to Pfizer’s News & Media Center—designed to give you immediate access to timely and relevant information about our company. In this section you will find information and resources for journalists including current and archived Pfizer press releases, a full company press kit, and a comprehensive collection of images and videos in our multimedia library.

June 12, 2013 — Pfizer Obtains $2.15 Billion Settlement from Teva and Sun for Infringement of Protonix® Patent

http://pfizer.newshq.businesswire.com/press-release/pfizer-obtains-215-billion-settlement-teva-and-sun-infringement-protonix-patent

Dateline City:

NEW YORK

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today a $2.15 billion settlement reached with Teva Pharmaceuticals Industries, Limited and Sun Pharmaceutical Industries, Limited for patent-infringement damages resulting from their "at-risk launches of generic Protonix® in the United States. The settlement comes after a nearly 10-year legal battle in which Pfizer and Nycomed (now part of Takeda) sought to enforce the patent for its blockbuster acid reflux medicine.

Language:

English

Contact:

Pfizer Inc.
Media Contact:
Chris Loder, 212-733-7897
or
Investor Contact:
Charles Triano, 212-733-3901

Ticker Slug:

Ticker:

PFE

Exchange:

NYSE

ISIN:

US7170811035

June 06, 2013 — Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

http://pfizer.newshq.businesswire.com/press-release/pfizer-invites-public-listen-webcast-pfizer-discussion-healthcare-conference-9

Dateline City:

NEW YORK

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Geno Germano, President and General Manager, Specialty Care and Oncology, at the Goldman Sachs 34^th Annual Global Healthcare Conference on Thursday, June 13, 2013 at 8:40 a.m. Pacific Daylight Time.

Language:

English

Contact:

Pfizer Inc.
Media Contact:
Joan Campion, 212-733-2798
or
Investor Contact:
Suzanne Harnett, 212-733-8009

Ticker Slug:

Ticker:

PFE

Exchange:

NYSE

ISIN:

US7170811035

June 05, 2013 — Americans Believe Their Communities Are Ill-Prepared For Aging Population, New Survey Reveals; Survey Shows A Fear Of Getting Old Due To Health And Financial Concerns

http://pfizer.newshq.businesswire.com/press-release/americans-believe-their-communities-are-ill-prepared-aging-population-new-survey-revea

Dateline City:

NEW YORK

Pfizer and Generations United Challenge People and Communities to Define How They Want to Get Old

NEW YORK--(BUSINESS WIRE)--Nearly nine out of ten people who live in the U.S. believe they will live a long life, yet 40 percent believe being old is something to fear due to potential health and financial concerns, according to the second annual Get Old survey.

Language:

English

Contact:

Pfizer Inc.
Media:
MacKay Jimeson, 212-733-2324

Ticker Slug:

Ticker:

PFE

Exchange:

NYSE

ISIN:

US7170811035

May 28, 2013 — Pfizer Prices $4.0 Billion Debt Offering

http://pfizer.newshq.businesswire.com/press-release/pfizer-prices-40-billion-debt-offering

Dateline City:

NEW YORK

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced the pricing of a debt offering consisting of five tranches of notes:

Language:

English

Contact:

Pfizer Inc.
Media Contact:
Joan Campion, 212-733-2798
or
Investor Contact:
Charles Triano, 212-733-3901

Ticker Slug:

Ticker:

PFE

Exchange:

NYSE

ISIN:

US7170811035

May 22, 2013 — Pfizer Announces Plan for Split-Off of Zoetis

http://pfizer.newshq.businesswire.com/press-release/pfizer-announces-plan-split-zoetis

Dateline City:

NEW YORK

Provides Pfizer shareholders an option for a tax-free exchange
Better positions Pfizer to focus on its core business as an innovative biopharmaceutical company
The completion of the full separation of Zoetis expected to be accretive to Pfizers EPS beginning in 2014

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced its intention to split off its remaining interest in Zoetis Inc. (NYSE: ZTS), through an exchange offer. Zoetis, formerly Pfizers animal health business, completed its initial public offering (IPO) in February 2013. In the exchange offer, Pfizer shareholders can exchange all, some or none of their shares of Pfizer common stock for shares of Zoetis common stock owned by Pfizer.

Language:

English

Contact:

Pfizer Inc.
Media:
Joan Campion, 212-733-2798
joan.campion@pfizer.com
Investor:
Chuck Triano, 212-733-3901
charles.e.triano@pfizer.com

Ticker Slug:

Ticker:

PFE

Exchange:

NYSE

ISIN:

US7170811035

Ticker:

ZTS

Exchange:

NYSE

May 20, 2013 — Pfizer Discontinues Phase 3 Study of Inotuzumab Ozogamicin in Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma (NHL) Due to Futility

http://pfizer.newshq.businesswire.com/press-release/pfizer-discontinues-phase-3-study-inotuzumab-ozogamicin-relapsed-or-refractory-aggress

Dateline City:

NEW YORK

Pfizer to Continue Evaluation of Inotuzumab Ozogamicin in Other Hematologic Malignancies

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today the discontinuation of a Phase 3 randomized, open-label, two-arm study (B1931008) evaluating the safety and efficacy of the investigational compound inotuzumab ozogamicin in patients with relapsed or refractory CD22+ aggressive non-Hodgkin lymphoma (NHL) who are not candidates for intensive high-dose chemotherapy.

Language:

English

Contact:

Pfizer Inc.
Media:
Victoria Davis, 484-865-5194
or
Investors:
Suzanne Harnett, 212-733-8009

Ticker Slug:

Ticker:

PFE

Exchange:

NYSE

ISIN:

US7170811035

Teleconference: Prevenar 13

Pfizer signs long-term agreement to supply Prevenar 13 to world's poorest countries.

Listen to Teleconference: Prevenar 13

Investor Presentations

Access the Pfizer Presentation Archive to view Executive Leadership presentations to shareholders, analysts, and global health care conferences.

Go to Presentations

Executive Speeches & Commentary

View Executive Leadership speeches on a variety of topics.

Go to Speeches

Pfizer Pipeline Update – Our Medicines in Development

Visit the Pfizer Pipeline to learn more about exciting breakthroughs with our medicines in development.

Pfizer Pipeline as of February 28, 2013

More Press Releases

Stay on top of Pfizer breaking news: Get News Alerts by RSS.

Stock Quote Disclaimer

20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.

Text SizeAAA

Stock Symbol: PFE Stock Exchange: NYSE

Stock Quote at: Jun 17 2013 4:00PM

Last 29.16

Change 0.07

%Change	0.24	Vol.	152,373,096
Day High	29.40	52 Wk. High	31.15
Day Low	28.90	52 Wk. Low	22.00
Open	29.40	Mkt. Cap(Bil)	206.84
Prev. Close	29.09

Cost Basis Calculator

Our press kit provides information that might help you write stories or simply find out more about Pfizer.

View the Pfizer Company Press Kit

Copyright © 2002–2013 Pfizer Inc. All rights reserved. This information is intended only for residents of the United States. The product information provided in this site is intended only for residents of the United States. The products discussed herein may have different product labeling in different countries. Pfizer Inc. is a pharmaceutical company committed to helping people improve their health by discovering and developing medicines.